KR101073590B1 - Ｉｌ-13에 대한 인간 항체 분자 - Google Patents

Ｉｌ-13에 대한 인간 항체 분자 Download PDF

Info

Publication number
KR101073590B1
KR101073590B1 KR1020067000933A KR20067000933A KR101073590B1 KR 101073590 B1 KR101073590 B1 KR 101073590B1 KR 1020067000933 A KR1020067000933 A KR 1020067000933A KR 20067000933 A KR20067000933 A KR 20067000933A KR 101073590 B1 KR101073590 B1 KR 101073590B1
Authority
KR
South Korea
Prior art keywords
ser
gly
seq
domain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020067000933A
Other languages
English (en)
Korean (ko)
Other versions
KR20060054312A (ko
Inventor
필립 데이빗 몽크
루츠 제르무투스
랄프 레이몬드 민터
셀리아 패트리시아 셜록
Original Assignee
메디뮨 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0407315.1A external-priority patent/GB0407315D0/en
Application filed by 메디뮨 리미티드 filed Critical 메디뮨 리미티드
Publication of KR20060054312A publication Critical patent/KR20060054312A/ko
Application granted granted Critical
Publication of KR101073590B1 publication Critical patent/KR101073590B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020067000933A 2003-07-15 2004-07-15 Ｉｌ-13에 대한 인간 항체 분자 Expired - Lifetime KR101073590B1 (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US48751203P 2003-07-15 2003-07-15
US60/487,512 2003-07-15
US55821604P 2004-03-31 2004-03-31
GB0407315.1 2004-03-31
US60/558,216 2004-03-31
GBGB0407315.1A GB0407315D0 (en) 2003-07-15 2004-03-31 Human antibody molecules
US57379104P 2004-05-24 2004-05-24
US60/573,791 2004-05-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020117003966A Division KR101168815B1 (ko) 2003-07-15 2004-07-15 Ｉｌ-13에 대한 인간 항체 분자

Publications (2)

Publication Number Publication Date
KR20060054312A KR20060054312A (ko) 2006-05-22
KR101073590B1 true KR101073590B1 (ko) 2011-10-14

Family

ID=44535047

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067000933A Expired - Lifetime KR101073590B1 (ko) 2003-07-15 2004-07-15 Ｉｌ-13에 대한 인간 항체 분자

Country Status (8)

Country Link
JP (3) JP5519567B2 (enExample)
KR (1) KR101073590B1 (enExample)
AU (1) AU2011200308B2 (enExample)
CY (1) CY1111467T1 (enExample)
HK (1) HK1216427A1 (enExample)
MX (1) MXPA06000258A (enExample)
NO (2) NO338853B1 (enExample)
RU (1) RU2009148270A (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201609980TA (en) * 2014-06-18 2016-12-29 Medimmune Llc Cell culture methods and media comprising n-acetylcysteine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035847A2 (en) * 2001-10-26 2003-05-01 Centocor, Inc. Il-13 mutein proteins, antibodies, compositions, methods and uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004680A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Human interleukin-13
ES2384100T3 (es) * 2001-12-03 2012-06-29 Alexion Pharmaceuticals, Inc. Método para producir anticuerpos híbridos
AU2003223497A1 (en) * 2002-04-05 2003-10-27 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
JP2006503018A (ja) * 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド ワクチン
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035847A2 (en) * 2001-10-26 2003-05-01 Centocor, Inc. Il-13 mutein proteins, antibodies, compositions, methods and uses

Also Published As

Publication number Publication date
JP2016047843A (ja) 2016-04-07
JP2014101372A (ja) 2014-06-05
HK1216427A1 (zh) 2016-11-11
JP5922686B2 (ja) 2016-05-24
NO342727B1 (no) 2018-07-30
CY1111467T1 (el) 2015-08-05
NO20060730L (no) 2006-04-10
KR20060054312A (ko) 2006-05-22
JP5519567B2 (ja) 2014-06-11
AU2011200308B2 (en) 2011-07-28
MXPA06000258A (es) 2006-07-03
RU2009148270A (ru) 2011-06-27
NO338853B1 (no) 2016-10-24
HK1097853A1 (en) 2007-07-06
JP2011147454A (ja) 2011-08-04
AU2011200308A1 (en) 2011-02-17
HK1155185A1 (en) 2012-05-11
NO20160707A1 (no) 2016-04-27

Similar Documents

Publication Publication Date Title
KR101168815B1 (ko) Ｉｌ-13에 대한 인간 항체 분자
US8506960B2 (en) Antibody molecule for human GM-CSF receptor alpha
JP4970258B2 (ja) ヒトインターロイキン−１３に対する抗体およびそれらの使用
KR20090088874A (ko) 인터루킨-6에 대한 결합 구성원
KR101073590B1 (ko) Ｉｌ-13에 대한 인간 항체 분자
HK1228920A1 (en) Neutralizing human antibody molecules for il-13
HK1097853B (en) Human antibody molecules for il-13
HK1228920A (en) Neutralizing human antibody molecules for il-13
HK1155185B (en) Human antibody molecules for il-13
HK1166989B (en) Binding member for gm-csf receptor
HK1193113B (en) Binding members for interleukin-6

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060113

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080627

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100820

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20110221

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20110831

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20111007

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20111010

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20140924

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20140924

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20150923

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20150923

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20160921

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20160921

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20170908

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20170908

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20181002

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20181002

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20190919

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20190919

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20200915

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20220915

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20230913

Start annual number: 13

End annual number: 13

PC1801 Expiration of term

Termination date: 20250115

Termination category: Expiration of duration